Quick Answer
Iterum Therapeutics plc reported R&D Expense of $10.46 million for fiscal year 2024.
Iterum Therapeutics plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $10.46M | -73.8% |
| 2023 | $39.99M | +127.0% |
| 2022 | $17.62M | +64.5% |
| 2021 | $10.71M | -49.2% |
| 2020 | $21.07M | -76.8% |
| 2019 | $90.77M | +32.2% |
| 2018 | $68.65M | +169.2% |
| 2017 | $25.50M | +152.4% |
| 2016 | $10.10M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.26M | -59.4% | +26.1% |
| June 30, 2025 | $1.00M | -51.8% | +69.2% |
| March 31, 2025 | $591.0K | -85.1% | -81.0% |
| September 30, 2024 | $3.11M | -79.1% | +49.7% |
| June 30, 2024 | $2.08M | -76.9% | -47.8% |
| March 31, 2024 | $3.98M | -38.2% | -73.2% |
| September 30, 2023 | $14.85M | +241.2% | +65.7% |
| June 30, 2023 | $8.96M | +125.0% | +39.4% |
- Iterum Therapeutics plc showed a decrease of -73.8% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2024 period, Iterum Therapeutics plc’s r&d expense has grown by 3.5% (from $10.10 million to $10.46 million).
- The most recent figure is from Iterum Therapeutics plc’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: